S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
pixel
What to Expect from the Markets in a Recession
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
pixel
What to Expect from the Markets in a Recession
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
pixel
What to Expect from the Markets in a Recession
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
pixel
What to Expect from the Markets in a Recession
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
NASDAQ:OMCL

Omnicell - OMCL Stock Forecast, Price & News

$109.12
-1.58 (-1.43%)
(As of 08/5/2022 08:49 PM ET)
Add
Compare
Today's Range
$103.62
$109.48
50-Day Range
$106.45
$124.09
52-Week Range
$103.62
$187.29
Volume
536,600 shs
Average Volume
506,174 shs
Market Capitalization
$4.82 billion
P/E Ratio
86.60
Dividend Yield
N/A
Price Target
$164.80

Omnicell MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
51.0% Upside
$164.80 Price Target
Short Interest
Healthy
7.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.04mentions of Omnicell in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$414,715 Sold Last Quarter
Proj. Earnings Growth
20.28%
From $2.81 to $3.38 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

136th out of 1,283 stocks

Electronic Computers Industry

5th out of 10 stocks

OMCL stock logo

About Omnicell (NASDAQ:OMCL) Stock

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

Omnicell Trading Down 1.4 %

NASDAQ:OMCL traded down $1.58 during trading hours on Friday, hitting $109.12. 536,608 shares of the company were exchanged, compared to its average volume of 361,801. The stock has a market capitalization of $4.82 billion, a price-to-earnings ratio of 86.60, a price-to-earnings-growth ratio of 3.53 and a beta of 1.04. Omnicell has a one year low of $103.62 and a one year high of $187.29. The company has a fifty day simple moving average of $112.76 and a 200 day simple moving average of $122.91.

Omnicell (NASDAQ:OMCL - Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The company reported $0.84 earnings per share for the quarter, missing the consensus estimate of $0.85 by ($0.01). Omnicell had a return on equity of 10.33% and a net margin of 4.82%. The business had revenue of $331.39 million during the quarter, compared to the consensus estimate of $339.45 million. During the same period last year, the business posted $0.71 earnings per share. The business's revenue was up 21.5% on a year-over-year basis. Equities research analysts predict that Omnicell will post 2.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on OMCL shares. SVB Leerink started coverage on Omnicell in a report on Friday, July 15th. They set a "market perform" rating and a $124.00 price objective on the stock. Wells Fargo & Company cut their price objective on Omnicell from $188.00 to $158.00 and set an "overweight" rating on the stock in a report on Tuesday, May 3rd. TheStreet downgraded Omnicell from a "b-" rating to a "c+" rating in a report on Tuesday, May 17th. BTIG Research lowered their target price on Omnicell from $190.00 to $175.00 and set a "buy" rating for the company in a research report on Wednesday, July 27th. Finally, Piper Sandler lowered their target price on Omnicell from $181.00 to $162.00 in a research report on Monday, May 2nd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $164.80.

Insider Transactions at Omnicell

In other news, EVP Scott Peter Seidelmann sold 3,765 shares of Omnicell stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of $110.15, for a total value of $414,714.75. Following the completion of the transaction, the executive vice president now directly owns 40,789 shares of the company's stock, valued at approximately $4,492,908.35. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.76% of the company's stock.

Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Stock News Headlines

Omnicell, Inc. (OMCL)
Omnicell: Q2 Earnings Snapshot
Omnicell Q2 2022 Earnings Preview - Seeking Alpha
See More Headlines
Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Company Calendar

Last Earnings
8/04/2022
Today
8/08/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electronic computers
Sub-Industry
Health Care Technology
Sector
Medical
Current Symbol
NASDAQ:OMCL
CUSIP
68213N10
Employees
3,800
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$164.80
High Stock Price Forecast
$205.00
Low Stock Price Forecast
$124.00
Forecasted Upside/Downside
+51.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$77.85 million
Pretax Margin
4.84%

Debt

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$5.35 per share
Book Value
$26.09 per share

Miscellaneous

Free Float
42,978,000
Market Cap
$4.82 billion
Optionable
Optionable
Beta
1.04

Social Links















OMCL Stock - Frequently Asked Questions

Should I buy or sell Omnicell stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Omnicell stock.
View analyst ratings for Omnicell
or view top-rated stocks.

What is Omnicell's stock price forecast for 2022?

5 Wall Street research analysts have issued 12-month price targets for Omnicell's stock. Their OMCL stock forecasts range from $124.00 to $205.00. On average, they anticipate Omnicell's stock price to reach $164.80 in the next year. This suggests a possible upside of 51.0% from the stock's current price.
View analysts' price targets for Omnicell
or view top-rated stocks among Wall Street analysts.

How has Omnicell's stock price performed in 2022?

Omnicell's stock was trading at $180.44 at the beginning of the year. Since then, OMCL shares have decreased by 39.5% and is now trading at $109.12.
View the best growth stocks for 2022 here
.

When is Omnicell's next earnings date?

Omnicell is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our earnings forecast for Omnicell
.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) posted its earnings results on Thursday, August, 4th. The company reported $0.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.85 by $0.01. The company had revenue of $331.39 million for the quarter, compared to analysts' expectations of $339.45 million. Omnicell had a trailing twelve-month return on equity of 10.33% and a net margin of 4.82%. The firm's quarterly revenue was up 21.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.71 earnings per share.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell updated its FY22 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of $3.85-4.05 for the period, compared to the consensus estimate of $3.90. The company issued revenue guidance of $1.385-1.410 billion, compared to the consensus revenue estimate of $1.40 billion.

What is Randall A. Lipps' approval rating as Omnicell's CEO?

150 employees have rated Omnicell CEO Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among Omnicell's employees.

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by a number of retail and institutional investors. Top institutional investors include Conestoga Capital Advisors LLC (3.80%), Geneva Capital Management LLC (1.90%), Scout Investments Inc. (0.71%), Stephens Investment Management Group LLC (0.60%), GAM Holding AG (0.48%) and Global Alpha Capital Management Ltd. (0.47%). Company insiders that own Omnicell stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends for Omnicell
.

How do I buy shares of Omnicell?

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $109.12.

How much money does Omnicell make?

Omnicell (NASDAQ:OMCL) has a market capitalization of $4.82 billion and generates $1.13 billion in revenue each year. The company earns $77.85 million in net income (profit) each year or $1.26 on an earnings per share basis.

How many employees does Omnicell have?

Omnicell employs 3,800 workers across the globe.

Does Omnicell have any subsidiaries?

The following companies are subsidiares of Omnicell: 340B Link Business, Aesynt, Aesynt B.V., Aesynt Holding B.V., Aesynt Holding Cooperatief U.A., Aesynt Pty Ltd., Aesynt S.r.l, Aruba S.r.l, Ateb Inc. , Health Robotics S.r.l., InPharmics, MTS Medication Technologies Inc., MTS Packing Systems Inc., Mach 4 Automatisierungs Technik GmbH, MedPak Holdings Inc., Omnicell (Beijing) Technology Co. Ltd., Omnicell GmbH, Omnicell International LLC, Omnicell Ltd., and Omnicell SAS.
Read More

When was Omnicell founded?

Omnicell was founded in 1992.

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for Omnicell is www.omnicell.com. The company can be reached via phone at (650) 251-6100, via email at ir@omnicell.com, or via fax at 847-596-3402.

This page (NASDAQ:OMCL) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.